Literature DB >> 23385421

Distinct claudin expression profiles of hepatocellular carcinoma and metastatic colorectal and pancreatic carcinomas.

Ágnes Holczbauer1, Benedek Gyöngyösi, Gábor Lotz, Attila Szijártó, Péter Kupcsulik, Zsuzsa Schaff, András Kiss.   

Abstract

Tight junction proteins, including claudins, are often dysregulated during carcinogenesis and tumor progression. Moreover, the claudin expression pattern usually varies between different tumor entities. We aimed to investigate claudin expression profiles of primary and metastatic liver malignancies. We analyzed claudin-1, -2, -3, -4, and -7 expression by quantitative immunohistochemistry and real-time RT-PCR, respectively. Twenty hepatocellular carcinomas (HCCs) and liver metastases of 20 colorectal adenocarcinomas (CRLMs) and 15 pancreatic adenocarcinomas (PLMs) were studied together with paired surrounding non-tumorous liver samples and 5 normal liver samples. Strong claudin-3 and -7 immunohistochemical positivities were detected in CRLM samples, each with significantly stronger staining when compared with HCC and PLM groups. Claudin-1 protein was found highly expressed in CRLM, in contrast to lower expression in PLM and HCC. CRLMs and PLMs also were strongly positive for claudin-4, while being virtually undetectable in HCC. Claudin-2 showed strong positivity in non-tumorous liver tissue, whereas significantly weaker positivity was observed in all tumors. Differences in mRNA expression were mostly similar to those found by immunohistochemistry. In conclusion, HCC and both CRLM and PLM display distinct claudin expression profiles, which might provide better understanding of the pathobiology of these lesions and might be used for differential diagnosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23385421      PMCID: PMC3636686          DOI: 10.1369/0022155413479123

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  68 in total

1.  Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells.

Authors:  Mercedes Lioni; Patricia Brafford; Claudia Andl; Anil Rustgi; Wafik El-Deiry; Meenhard Herlyn; Keiran S M Smalley
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

2.  Differential expression of claudin-2 in normal human tissues and gastrointestinal carcinomas.

Authors:  Phyu Phyu Aung; Yoshitsugu Mitani; Yuichi Sanada; Hirofumi Nakayama; Keisuke Matsusaki; Wataru Yasui
Journal:  Virchows Arch       Date:  2005-11-17       Impact factor: 4.064

Review 3.  New signals from the invasive front.

Authors:  Gerhard Christofori
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

4.  Loss of claudin-1 expression correlates with malignancy of hepatocellular carcinoma.

Authors:  Yukihiro Higashi; Shohachi Suzuki; Takanori Sakaguchi; Toshio Nakamura; Satoshi Baba; Hans-Christian Reinecker; Satoshi Nakamura; Hiroyuki Konno
Journal:  J Surg Res       Date:  2007-01-30       Impact factor: 2.192

5.  Reduced expression of claudin-7 correlates with invasion and metastasis in squamous cell carcinoma of the esophagus.

Authors:  Yu Usami; Hideki Chiba; Fumihito Nakayama; Junya Ueda; Yoshiko Matsuda; Norimasa Sawada; Takahide Komori; Akihiko Ito; Hiroshi Yokozaki
Journal:  Hum Pathol       Date:  2006-05       Impact factor: 3.466

Review 6.  Pathology of liver metastases.

Authors:  Barbara A Centeno
Journal:  Cancer Control       Date:  2006-01       Impact factor: 3.302

7.  Claudin-1 acts through c-Abl-protein kinase Cdelta (PKCdelta) signaling and has a causal role in the acquisition of invasive capacity in human liver cells.

Authors:  Chang-Hwan Yoon; Min-Jung Kim; Myung-Jin Park; In-Chul Park; Sang-Gu Hwang; Sungkwan An; Yung-Hyun Choi; Gyesoon Yoon; Su-Jae Lee
Journal:  J Biol Chem       Date:  2009-11-06       Impact factor: 5.157

Review 8.  Claudins as diagnostic and prognostic markers in gynecological cancer.

Authors:  I Szabó; A Kiss; Z Schaff; G Sobel
Journal:  Histol Histopathol       Date:  2009-12       Impact factor: 2.303

9.  Claudin-1 protein is a major factor involved in the tumorigenesis of colorectal cancer.

Authors:  Qun Huo; Tetsushi Kinugasa; Lin Wang; Jian Huang; Jun Zhao; Hirotomo Shibaguchi; Motomu Kuroki; Toshihiro Tanaka; Yuichi Yamashita; Kazuki Nabeshima; Hiroshi Iwasaki; Masahide Kuroki
Journal:  Anticancer Res       Date:  2009-03       Impact factor: 2.480

10.  Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.

Authors:  Masayo Suzuki; Mariko Kato-Nakano; Shinobu Kawamoto; Akiko Furuya; Yuzuru Abe; Hirofumi Misaka; Naoya Kimoto; Kazuyasu Nakamura; So Ohta; Hiroshi Ando
Journal:  Cancer Sci       Date:  2009-06-01       Impact factor: 6.716

View more
  12 in total

Review 1.  Targeting tight junctions during epithelial to mesenchymal transition in human pancreatic cancer.

Authors:  Daisuke Kyuno; Hiroshi Yamaguchi; Tatsuya Ito; Tsuyoshi Kono; Yasutoshi Kimura; Masafumi Imamura; Takumi Konno; Koichi Hirata; Norimasa Sawada; Takashi Kojima
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Mutations in TJP2 cause progressive cholestatic liver disease.

Authors:  Melissa Sambrotta; Sandra Strautnieks; Efterpi Papouli; Peter Rushton; Barnaby E Clark; David A Parry; Clare V Logan; Lucy J Newbury; Binita M Kamath; Simon Ling; Tassos Grammatikopoulos; Bart E Wagner; John C Magee; Ronald J Sokol; Giorgina Mieli-Vergani; Joshua D Smith; Colin A Johnson; Patricia McClean; Michael A Simpson; A S Knisely; Laura N Bull; Richard J Thompson
Journal:  Nat Genet       Date:  2014-03-09       Impact factor: 38.330

3.  The role of hepatocyte nuclear factor 4-alpha in perfluorooctanoic acid- and perfluorooctanesulfonic acid-induced hepatocellular dysfunction.

Authors:  Kevin M Beggs; Steven R McGreal; Alex McCarthy; Sumedha Gunewardena; Jed N Lampe; Christoper Lau; Udayan Apte
Journal:  Toxicol Appl Pharmacol       Date:  2016-05-03       Impact factor: 4.219

4.  Increased expression of claudin-1 and claudin-7 in liver cirrhosis and hepatocellular carcinoma.

Authors:  Ágnes Holczbauer; Benedek Gyöngyösi; Gábor Lotz; Péter Törzsök; Pál Kaposi-Novák; Attila Szijártó; Péter Tátrai; Péter Kupcsulik; Zsuzsa Schaff; András Kiss
Journal:  Pathol Oncol Res       Date:  2014-04-03       Impact factor: 3.201

5.  Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis.

Authors:  Sébastien Tabariès; Matthew G Annis; Brian E Hsu; Christine E Tam; Paul Savage; Morag Park; Peter M Siegel
Journal:  Oncotarget       Date:  2015-04-20

6.  Claudin-4 activity in ovarian tumor cell apoptosis resistance and migration.

Authors:  Douglas A Hicks; Carly E Galimanis; Patricia G Webb; Monique A Spillman; Kian Behbakht; Margaret C Neville; Heidi K Baumgartner
Journal:  BMC Cancer       Date:  2016-10-11       Impact factor: 4.430

7.  Expression of hnRNPK & Claudin-4 in HCV-Induced Early HCC and Adjacent Liver Tissue.

Authors:  Olfat Hammam; Mona Magdy; Amgad Anas; Ali Abdel Rahim; Mohamed Heedaya; Ahmed Helmy
Journal:  Open Access Maced J Med Sci       Date:  2017-07-31

8.  Romidepsin hepatocellular carcinoma suppression in mice is associated with deregulated gene expression of bone morphogenetic protein and Notch signaling pathway components.

Authors:  Hara Afaloniati; Theofilos Poutahidis; Alexander Giakoustidis; Athanasios Gargavanis; Dimitrios Giakoustidis; Katerina Angelopoulou
Journal:  Mol Biol Rep       Date:  2021-01-03       Impact factor: 2.316

Review 9.  Claudin-1, A Double-Edged Sword in Cancer.

Authors:  Ajaz A Bhat; Najeeb Syed; Lubna Therachiyil; Sabah Nisar; Sheema Hashem; Muzafar A Macha; Santosh K Yadav; Roopesh Krishnankutty; Shanmugakonar Muralitharan; Hamda Al-Naemi; Puneet Bagga; Ravinder Reddy; Punita Dhawan; Anthony Akobeng; Shahab Uddin; Michael P Frenneaux; Wael El-Rifai; Mohammad Haris
Journal:  Int J Mol Sci       Date:  2020-01-15       Impact factor: 5.923

Review 10.  Tight Junctions in Cell Proliferation.

Authors:  Mónica Díaz-Coránguez; Xuwen Liu; David A Antonetti
Journal:  Int J Mol Sci       Date:  2019-11-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.